Vetter's Contribution to Climate Protection
The largest meeting to accelerate oligunucleotide and peptide products from discovery to commercialization.
Small filling runs create unique challenges. See how Vetter and Syntegon are combining their expertise to solve them
How Global Trends Are Driving Patient-Centricity in Parenteral Products.
After only one year our location in Austria has been modified to the high Vetter quality standards.
The key to successful development and guiding a drug to approval is early planning.
Fast, safe and efficient: the new Vetter ID determination of oligonucleotides.
92 percent of our colleagues in Chicago named Vetter a “Great Place to Work” company!
In this article Senior Vice President Kai Vogt talks about the opportunities of digital transformation at Vetter.
Renewed award confirms continuity and the approach to sustainability.
Rentschler Biopharma and Vetter announced today that their strategic collaboration has taken key steps forward.
Interview with Oskar Gold, SVP Asia Pacific and Global Emerging Markets